Insight

KRAS mutations and biliary tract cancers by Rebecca Gelfer et al.

Rebecca Gelfer/cornell.edu

Dec 10, 2024, 05:34

KRAS mutations and biliary tract cancers by Rebecca Gelfer et al.

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post X:

“KRAS mutations and biliary tract cancers JCO Precision Oncology.

Mutation frequency: 15%
KRAS G12D was the most common
KRAS G12 mutations worse OS in intrahepatic CCA
KRAS-targeted treatments.

Title: KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers

Authors: Rebecca Gelfer, Aiste Gulla, Hannah L. Kalvin, Yi Song, James Harding, Ghassan K. Abou-Alfa, Eileen M. O’Reilly, Wungki Park, Rohit Chandwani, Alice Wei, Peter Kingham, Jeffrey Drebin, Vinod Balachandran, Michael D’Angelica, Kevin Soares, Mithat Gonen and William R. Jarnagin

KRAS mutations

Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.

More posts featuring Erman Akkus.

Aiste Gulla Ankara University biliary tract Biliary tract cancers cancer Erman Akkus Genomic Hannah L. Kalvin intrahepatic JCO Precision Oncology Kevin Soares KRAS mutations Mithat Gönen OncoDaily Oncology Rebecca Gelfer treatments William R. Jarnagin Yi Song

Wanda Sykes and Breast Cancer: How She Went Against, How She Survived, and More

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 2

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 1

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Have faith in yourself, and look out for the bad man - reflections from Neil Ranasinghe's involvement in LGCW

Special Coverage